Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Irinotecan + SR-4835|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|SR-4835||SR-4835 selectively inhibits CDK12 and CDK13, impairs DNA damage response, which potentially leads to inhibition of cell proliferation and tumor growth (PMID: 31668947).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Irinotecan + SR-4835||Preclinical - Pdx||Actionable||In a preclinical study, SR-4835 and Camptosar (irinotecan) combination treatment induced DNA damage and cell death, inhibited tumor growth, leading to tumor regression in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring a BRCA1 mutation (PMID: 31668947).||31668947|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|